Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

BHC vs AVDL: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

AVDL Captures Overall Composite Edge (62.9 BUY vs 44.1 HOLD), While BHC Leads 5–1 on Growth & Valuation Pillars

AVDL Overall Winner 6-Pillar Tally: BHC 5 – 1 AVDL Matrix Metrics: BHC 4 – 6 AVDL

As of Nov 20, 2026, Avadel Pharmaceuticals plc Ordinary Share (AVDL) captures the overall head-to-head institutional edge over Bausch Health Companies Inc (BHC) on higher Unified Composite conviction (62.9/100 BUY vs. 44.1/100 HOLD) after splitting the core matrix 6–4 (led by Profitability & Quality), while BHC wins 5–1 across the 6-pillar growth and valuation breakdown. BHC trades at $8.22 (1.9x Forward P/E, 27.2% operating margin) versus AVDL at $21.64 (28.8x Forward P/E, 2.5% operating margin).

  • Growth vs. Quality Trade-Off: AVDL earns the overall head-to-head edge with a stronger Unified Composite Score (62.9/100 BUY vs. BHC 44.1/100 HOLD) and 0.14β · 2% Vol risk profile, whereas BHC leads top-line expansion (+9.7% YoY revenue growth, 0.01x PEG, and 5 of 6 institutional pillars) for higher-beta growth mandates.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About BHC vs AVDL
BHC NYSE
Bausch Health Companies Inc
Pharmaceutical Preparations
$8.22
-3.97% 1D
Market Cap $3.2B
TTM Revenue $11.1B
Forward P/E 1.9x
Beta / 30D Vol 0.96β · 111% Vol
Unified Composite Score
44.1 / 100 HOLD
Tech 32.0 Fund 47.0 Flow 70.0 Mom 41.1
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (10.1% over 20 days), RSI 59
RSI-14: 58.5 · SMA20: $8.07 · SMA50: $6.80
AVDL NASDAQ Head-to-Head Winner
Avadel Pharmaceuticals plc Ordinary Share
Pharmaceutical Preparations
$21.64
+0.05% 1D
Market Cap $2.1B
TTM Revenue $249M
Forward P/E 28.8x
Beta / 30D Vol 0.14β · 2% Vol
Unified Composite Score
62.9 / 100 BUY
Tech 75.0 Fund 60.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (1.4% over 20 days), RSI 62
RSI-14: 62.3 · SMA20: $21.56 · SMA50: $21.50

6-Pillar Scorecard Institutional Category Breakdown (BHC 5 – 1 AVDL)

Columns: Metric · BHC · AVDL
1. Valuation Multiples BHC
Forward P/E 1.9x 28.8x
Trailing P/E 2.0x 16.8x
PEG Ratio 0.01x 0.07x
EV / Revenue 0.3x 8.5x
2. Growth & Scale BHC
Revenue Growth (YoY) +9.7% +54.9%
Earnings Growth (YoY) +139.6% +0.0%
TTM Revenue (USD) $11.1B $249M
Market Cap $3.2B $2.1B
3. Profitability & Quality AVDL
Gross Margin 72.6% 94.9%
Operating Margin 27.2% 2.5%
Net Profit Margin -7.6% -0.1%
Return on Equity (ROE) -11040.0% -0.3%
4. Balance Sheet & Cash Flow BHC
Cash Generation (TTM) $1.83B $2.7M EBITDA
Cash Flow Margin 16.4% 1.1% EBITDA Mgn
Net Cash / Leverage -11040.0% ROE $1.01 Book/Sh · -0.3% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning BHC
Options Structure Phase BREAKOUT UNCLASSIFIED
Current IV / %ile 471.5% (100th %ile) 2.4% (<1st %ile)
Put/Call OI Skew 0.13x (Call-Skewed) N/A
OBV Trend / Tech Phase ACCUMULATION · Markup NEUTRAL · Markup
6. R&D & Supply-Chain Moat BHC
OpEx & R&D Intensity 45.4% of Rev ($5.05B) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Scale & Operating Efficiency Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Drug Manufacturers - Specialty & Generic Operator Drug Manufacturers - Specialty & Generic Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: BHC (4) vs AVDL (6)
Institutional Metric BHC AVDL Criterion Row Edge
Market Capitalization
Scale
$3.2B $2.1B Larger Scale BHC
Trailing P/E Ratio
Valuation
2.0x 16.8x Lower Multiple BHC
Forward P/E Ratio
Valuation
1.9x 28.8x Lower Multiple BHC
Revenue Growth (YoY)
Growth
+9.7% +54.9% Higher Growth AVDL
Operating Margin (TTM)
Profitability
27.2% 2.5% Higher Margin BHC
Net Profit Margin
Profitability
-7.6% -0.1% Higher Margin AVDL
Return on Equity (ROE)
Capital Efficiency
-11040.0% -0.3% Higher ROE AVDL
52-Week Range Position
Momentum
83% ($4–$9) 89% ($6–$24) Stronger Trend AVDL
Beta / 30D Volatility
Risk Regime
0.96β · 111% Vol 0.14β · 2% Vol Lower Realized Risk AVDL
Unified Institutional Score
Composite Signal
44.1 / 100 (HOLD) 62.9 / 100 (BUY) Higher Composite AVDL
Trailing 12M Revenue (USD)
Operating Scale
$11.1B $249M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
72.6% 94.9% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
0.01x PEG · 0.3x EV/Rev 0.07x PEG · 8.5x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$1.83B (-11040.0% ROE) $2.7M EBITDA ($1.01 Book/Sh · -0.3% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon AVDL +19.48 pp
BHC: -18.83% · AVDL: +0.65%
3M Horizon BHC +6.82 pp
BHC: +0.5% · AVDL: -6.32%
6M Horizon BHC +6.82 pp
BHC: +0.5% · AVDL: -6.32%
1Y Horizon BHC +6.82 pp
BHC: +0.5% · AVDL: -6.32%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BHC vs AVDL. Trailing 12-month operating profitability (BHC 27.2% vs AVDL 2.5%) and valuation multiples (BHC 1.9x vs AVDL 28.8x Forward P/E) are benchmarked directly in Pillar 4 below.

BHC ADR TTM Benchmark FX-Normalized USD
TTM Revenue$11.1B
Gross Margin72.6%
Op. Margin27.2%
ROE / Fwd P/E-11040.0% · 1.9x
AVDL ADR TTM Benchmark FX-Normalized USD
TTM Revenue$249M
Gross Margin94.9%
Op. Margin2.5%
ROE / Fwd P/E-0.3% · 28.8x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
BHC BREAKOUT
78d in phase · OBV ACCUMULATION
Current IV 471.5%
IV Percentile 100th %ile
Put/Call OI Skew 0.13x (Call-Skewed)
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact BHC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
AVDL UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 2.4%
IV Percentile <1st %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact AVDL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
BHC Moat Profile Scale & Operating Efficiency Moat
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $3.2B market capitalization and 27.2% operating margin.
OpEx & R&D Reinvestment 45.4% of Rev ($5.05B)
90D Engineering Disclosures 0 Published
AVDL Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $2.1B market capitalization and 2.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ BHC vs AVDL Key Questions & Quantitative Answers

As of Nov 20, 2026, Avadel Pharmaceuticals plc Ordinary Share (AVDL) captures the overall head-to-head institutional edge over Bausch Health Companies Inc (BHC) on higher Unified Composite conviction (62.9/100 BUY vs. 44.1/100 HOLD) after splitting the core matrix 6–4 (led by Profitability & Quality), while BHC wins 5–1 across the 6-pillar growth and valuation breakdown. BHC trades at $8.22 (1.9x Forward P/E, 27.2% operating margin) versus AVDL at $21.64 (28.8x Forward P/E, 2.5% operating margin). Growth vs. Quality Trade-Off: AVDL earns the overall head-to-head edge with a stronger Unified Composite Score (62.9/100 BUY vs. BHC 44.1/100 HOLD) and 0.14β · 2% Vol risk profile, whereas BHC leads top-line expansion (+9.7% YoY revenue growth, 0.01x PEG, and 5 of 6 institutional pillars) for higher-beta growth mandates.

BHC leads the Growth & Scale pillar: BHC posts +9.7% YoY revenue growth and +139.6% YoY earnings growth on $11.1B TTM revenue (72.6% gross margin, 27.2% operating margin), compared with AVDL at +54.9% YoY revenue growth and +0.0% YoY earnings growth on $249M TTM revenue (94.9% gross margin, 2.5% operating margin). On trailing 12-month operating scale, BHC generates $11.1B in USD-normalized revenue versus $249M for AVDL. In operating R&D and SG&A reinvestment, BHC deploys 45.4% of Rev ($5.05B) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for AVDL.

BHC screens cheaper on headline valuation multiples. BHC trades at 1.9x Forward P/E, 2.0x Trailing P/E, 0.01x PEG, and 0.3x EV/Revenue (16.4% FCF margin), whereas AVDL trades at 28.8x Forward P/E, 16.8x Trailing P/E, 0.07x PEG, and 8.5x EV/Revenue (1.1% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BHC (-11040.0% ROE) versus AVDL (-0.3% ROE) capital efficiency.

In options market volatility and institutional positioning, BHC carries 471.5% implied volatility (100th %ile, Extreme (>80th %ile)), a 0.13x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKOUT options structure phase (0.96β · 111% Vol realized risk). By comparison, AVDL carries 2.4% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.14β · 2% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.